Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Pancreatic Neoplasms 4Resectable Pancreatic Cancer 1Prostatic Neoplasms 1Neoplasm Metastasis 1Adenocarcinoma 1

Interventions

Prednisone 112Docetaxel 87Leuprolide 79enzalutamide 72Abiraterone Acetate 67bicalutamide 53Goserelin 50acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 42Radiotherapy 39abiraterone 28Magnetic Resonance Spectroscopy 26Gonadotropin-Releasing Hormone 24gallium 68 PSMA-11 23apalutamide 22Androgen Antagonists 22luprolide acetate gel depot 21sipuleucel-T 20Radiosurgery 20Triptorelin Pamoate 18cabazitaxel 17Radiotherapy, Intensity-Modulated 16Flutamide 16pembrolizumab 15cabozantinib 15radium Ra 223 dichloride 14Prednisolone 14Dutasteride 14Dexamethasone 14Radiation 13Nivolumab 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Prostatic Neoplasms × paricalcitol × Clear all
NCT00634582 2018-07-06

Paricalcitol in Treating Patients With Advanced Prostate Cancer and Bone Metastases

Wake Forest University Health Sciences

Phase 2 Terminated
2 enrolled 6 charts
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡